Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNotes PayablesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

CNBX Pharmaceuticals (CNBX) Common Equity (2016 - 2025)

CNBX Pharmaceuticals (CNBX) has disclosed Common Equity for 14 consecutive years, with -$2.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Common Equity fell 2.33% year-over-year to -$2.6 million, compared with a TTM value of -$2.6 million through Nov 2025, down 2.33%, and an annual FY2025 reading of -$2.5 million, down 0.66% over the prior year.
  • Common Equity was -$2.6 million for Q4 2025 at CNBX Pharmaceuticals, down from -$2.5 million in the prior quarter.
  • Across five years, Common Equity topped out at $3.8 million in Q1 2021 and bottomed at -$2.6 million in Q4 2025.
  • Average Common Equity over 5 years is -$1.1 million, with a median of -$2.0 million recorded in 2023.
  • The sharpest move saw Common Equity grew 21.41% in 2021, then tumbled 345.95% in 2022.
  • Year by year, Common Equity stood at $802708.0 in 2021, then crashed by 345.95% to -$2.0 million in 2022, then fell by 6.11% to -$2.1 million in 2023, then decreased by 20.02% to -$2.5 million in 2024, then decreased by 2.33% to -$2.6 million in 2025.
  • Business Quant data shows Common Equity for CNBX at -$2.6 million in Q4 2025, -$2.5 million in Q3 2025, and -$2.5 million in Q2 2025.